China Academy of Chinese Medical Sciences is the lead sponsor of 3 current clinical trials in our China register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Observational. The drugs named most often in its trials are Yiqi Fumai. The most-studied condition is Chronic Heart Failure.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
NCT07803471 · ClinicalTrials.gov ↗ · Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
Drug: Yiqi Fumai |
Not applicable | Not yet open | 2026-09 | China |
|
Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis
NCT07319338 · ClinicalTrials.gov ↗ · Chronic Atrophic Gastritis, Depressive Symptoms, Depression
|
Observational | Not yet open | 2026-02 | China |
|
Real-World Effectiveness and Costs of Yiqi Fumai Lyophilized Injection in Coronary Heart Disease-Related Chronic Heart Failure
NCT07841275 · ClinicalTrials.gov ↗ · Chronic Heart Failure, Coronary Heart Disease (CHD)
Drug: Yiqi Fumai |
Observational | Not yet open | 2026-09 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Pr. Nicolas GIRERD | 2 |
| Heartfelt Technologies | 1 |
| Pharmacosmos | 1 |
| Puerta de Hierro University Hospital | 1 |
| Regionshospital Nordjylland | 1 |
| Duke-NUS Graduate Medical School | 1 |
Sponsors with the most current trials registered for this condition.
China Academy of Chinese Medical Sciences is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 5 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Yiqi Fumai (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 5 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
